FRANKFURT, Oct 23 (Reuters) - Roche's CEO on

Thursday showed full confidence in the drugmaker's bets on

future weight-loss drug market growth, even after a board room

shake-up at the pioneer in the segment, Novo Nordisk,

over disappointing sales.

"I don't think that we are overestimating the market, we are

only scratching the surface of the market," Roche CEO Thomas

Schinecker said in a media call after the publication of

nine-month sales figures.

He highlighted promising treatment approaches pursued by

Roche, such as dual modes of action as well as treatment

mechanisms linked to the metabolic hormone amylin.